Jonathan Rigby, MD, President, Group CEO, and Board Member at Revolo Biotherapeutics, gives an overview of eosinophilic esophagitis (EoE).

As Dr. Rigby explains, EoE is a chronic, allergic inflammatory disease that is characterized by the buildup of eosinophils in the lining of the esophagus. Patients with EoE often experience difficulty feeding, poor weight gain, and trouble swallowing. 

Currently, there is no approved treatment specifically for EoE. Standard of care includes steroids, which require frequent dosing and are often associated with unwanted side effects, such as immune suppression. Fortunately, Revolo has recently received approval to begin a phase 2 trial of the drug, ‘1104, for the treatment of EoE. For more information about this study, go here.

To learn more about EoE and other rare autoimmune disorders, visit